VEMURAFENIB

作品数：21被引量：18H指数：3
导出分析报告
相关领域：医药卫生更多>>
相关作者：刘蓉谢宗宙林飞燕王泉江涂超更多>>
相关机构：广东医科大学山西医科大学海口市人民医院中南大学湘雅二医院更多>>
相关期刊：《药学进展》《Acta Pharmacologica Sinica》《世界临床药物》《中国药物化学杂志》更多>>
相关基金：国家自然科学基金上海市自然科学基金山西省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Transdermal treatment for malignant melanoma by aptamer-modified tetrahedral framework nucleic acid delivery of vemurafenib
《Chinese Chemical Letters》2024年第4期260-267,共8页Dexuan Xiao Tianyu Chen Tianxu Zhang Sirong Shi Mei Zhang Xin Qin Yunkun Liu Longjiang Li Yunfeng Lin 
supported by National Key R&D Program of China (No.2019YFA0110600);National Natural Science Foundation of China (No.81970916);Sichuan Science and Technology Program(No.2022NSFSC0002);Sichuan Province Youth Science and Technology Innovation Team (No.2022JDTD0021);Research and Develop Program;West China Hospital of Stomatology Sichuan University (No.RD03202302)。
Melanoma is one of the most malignant skin tumors, whose high invasion is generally associated with BRAF gene mutation. Although new chemotherapeutic drugs, such as vemurafenib, have been developed to inhibit the grow...
关键词：MELANOMA VEMURAFENIB DNA nanostructure Transdermal treatment Side effect 
PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas
《Cancer Biology & Medicine》2022年第8期1211-1223,共13页Junling Shen Jilong Yang Lei Sang Rui Sun Weiyu Bai Chao Wang Yan Sun Jianwei Sun 
supported by National Natural Science Foundation of China(Grant Nos.81871990 and 31671448);Yunnan Applicative and Basic Research Program(Grant Nos.2019FY003030 and 202101AV070002);a grant(2019KF006)from Conservation and Utilization of Bio-Resources in Yunnan(YNCUB).
Objective:The BRAF inhibitor,vemurafenib,has been widely used in the treatment of patients with melanoma-bearing BRAFV600E mutations.While the initial response to vemurafenib is usually excellent,the majority of patie...
关键词：STIM1 PYK2 INVADOPODIA INVASION MELANOMA VEMURAFENIB 
Identification of HMGCR as the anticancer target of physapubenolide against melanoma cells by in silico target prediction
《Acta Pharmacologica Sinica》2022年第6期1594-1604,共11页Hai-yan Wang Pian Yu Xi-sha Chen Hui Wei Shi-jie Cao Meng Zhang Yi Zhang Yong-guang Tao Dong-sheng Cao Feng Qiu Yan Cheng 
This work was supported by the National Natural Science Foundation of China under Grant Nos.81972480 and 21472138;National Science and Technology Major Project(2017ZX09301012);The Key Research and Development Program of Hunan Province(2019DK2011);Scientific Research Project of Hunan Provincial Health Commission(202102080940);Vemurafenib-resistant A-375 cells were a gift from Cong Peng,Xiangya Hospital,Central South University.
Physapubenolide(PB),a withanolide-type compound extracted from the traditional herb Physalis minima L.,has been demonstrated to exert remarkable cytotoxicity against cancer cells;however,its molecular mechanisms are s...
关键词：physapubenolide melanoma cells HMGCR VEMURAFENIB drug resistance 
Theoretical Study of Adsorption Behavior of Vemurafenib Drug over BNNT(5,5-9) as a Factor of Drug Delivery: a DFT Study
《Chinese Journal of Structural Chemistry》2020年第8期1422-1436,1358,共16页MASOOME Sheikhi SIYAMAK Shahab HORA Alhosseini Almodarresiyeh MEHRNOOSH Khaleghian RAKESH Kumar ALEKSANDRA Strogova 
supported by the National Academy of Sciences of Belarus。
In this research,a density functional theory(DFT)calculation was performed for investigation adsorption behavior of the anticancer drug Vemurafenib on BNNT(5,5-9)by using the M06-2X/6-31 G*level of theory in the solve...
关键词：VEMURAFENIB BNNT(5 5-9) DFT charge transfer NBO 
Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics被引量：4
《Cancer Biology & Medicine》2019年第2期247-263,共17页Jelena Grahovac Tatjana Srdic-Rajic Juan Francisco Santibanez Marijana Pavlovic Milena Cavic Sinisa Radulovic1 
supported by grants from the Serbian Ministry for Education, Science and Technology Development (Grant No.III41026 and 175053)
Objective: Despite recent advancements in targeted therapy and immunotherapies, prognosis for metastatic melanoma patients remains extremely poor. Development of resistance to previously effective treatments presents ...
关键词：MELANOMA TELMISARTAN apoptosis MITOCHONDRIA reactive oxygen species targeted therapy 
siPGK1在调控黑色素瘤细胞对Vemurafenib敏感性中的作用及其机制
《中国应用生理学杂志》2017年第4期289-293,共5页刘蓉 宛欣 王茜 李凡璐 景佳妮 崔香丽 
国家自然科学基金(81272695);山西省自然科学基金(2012011040-8);山西医科大学科技创新基金([2012]11)
目的:研究磷酸甘油酸酯激酶1(PGK1)对BRAFV600E突变型恶性黑色素瘤(MM)对Vemurafenib(Zelboraf)敏感性的影响及其机制。方法:采用分子生物学、细胞生物学、药理学相关实验方法(MTT、Western blot、FCM、Colongenic)探讨:(1)PGK1以及Ve...
关键词：黑色素瘤 siPGK1 VEMURAFENIB 细胞凋亡 
Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Rafv600E inhibitors
《Acta Pharmacologica Sinica》2017年第7期1059-1068,共10页Gui-min WANG Xiang WANG Jian-ming ZHU Bin-bin GUO Zhuo YANG Zhi-jian XU Bo LI He-yao WANG Ling-hua MENG Wei-liang ZHU Jian DING 
This work was supported by the National Natural Science Foundation of China （81273435, 81302699 and 81321092）, the National Science and Technology Major Project （2013ZX09103001001）, the Ministry of Science and Technology （2012AA01A305）, the Natural Science Foundation of Shanghai, China （14ZR1447800）, the State Key Laboratory of Natural and Biomimetic Drugs （K20150205） and the Special Program for Applied Research on Super Computation of the NSFC-Guang- dong Joint Fund （the second phase）.
The mutation of B-Rafv600E is widespread in a variety of human cancers. Its inhibitors vemurafenib and dabrafenib have been launched as drugs for treating unresectable melanoma, demonstrating that B-Rafv600E is an ide...
关键词：B-Rafv600E inhibitor anticancer VEMURAFENIB deazapurine fragment reassembly molecular docking STRUCTURE-ACTIVITYRELATIONSHIP 
Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review被引量：2
《Chinese Journal of Cancer》2017年第4期202-206,共5页Aurélien Simon Hampig Raphael Kourie Joseph Kerger 
Metastatic melanoma has long been considered to have a very poor prognosis and to be chemo-resistant. However, a subgroup of patients with metastatic melanoma presents remarkable responses to chemotherapeutic agents, ...
关键词：METASTATIC MELANOMA Chemotherapy IMMUNOTHERAPY CHECKPOINT inhibitors VEMURAFENIB ATM mutation CHEMOSENSITIVITY 
抗黑色素瘤新药cobimetinib被引量：1
《中国新药杂志》2016年第21期2401-2404,共4页张莹 刘波 胡金成 赵健琦 
黑色素瘤是由黑色素细胞引发的恶性肿瘤。2015年11月10日,美国FDA批准cobimetinib（商品名：Cotellic ）联合vemurafenib（商品名：Zelboraf ）治疗伴有B-RAF^V600E或B-RAF^V600K突变的不可切除或转移性黑色素瘤。vemurafenib和cobi...
关键词：cobimetinib VEMURAFENIB 黑色素瘤 
A plant sesquiterpene lactone and its derivative reduce cutaneous side effect of vemurafenib,a BRAF inhibitor drug to treat late stage melanoma
《中国药理学与毒理学杂志》2015年第S1期90-91,共2页Meng-ting CHANG Jia-hua FENG Kyoko NAKAGAWA-GOTO Kuo-Hsiung LEE Lie-Fen SHYUR 
The project supported by a research grant from Ministry of Science and Technology(MOST 103-2320-B-001-008-MY3),Chinese Taipei
OBJECTIVE To investigate the pharmacological effect of a plant sesquiterpene lactone(designated D)and its semi-organically synthesized novel derivative(designated S)and the role of lipid mediators,viz.,oxylipins in at...
关键词：VEMURAFENIB SESQUITERPENE LACTONE two-stage carcin 
全选清除导出
共3页<123>
检索报告 对象比较 聚类工具 使用帮助 返回顶部